In Phase 2 studies, researchers administer the drug to a group of patients with the disease or condition for which the drug is being developed. FDA responds to IND applications in one of two ways: Clinical hold to delay or stop the investigation. A study of clinical trials conducted in the United States from 2004 to 2012 found the average cost of Phase I trials to be between $1.4 million and $6.6 million, depending on 6 hours ago. /*-->